Coronavirus company news summary – Abbott ID NOW point-of-care test may give false negative results – MedC2 receives €860,000 subsidy from European Commission

15 May 2020 (Last Updated May 15th, 2020 09:49)

The US Food and Drug Administration (FDA) has announced that the Abbott ID NOW point-of-care test, which is used to detect Covid-19, may offer inaccurate results. The FDA is currently working with Abbott to examine the data and formulate a customer notification letter with the company, to alert users regarding the false negative tests that may be inconsistent with the symptoms of the patient.

BGI has announced that Sinai Health will receive a donation of essential laboratory equipment from the Mammoth Foundation to boost its Covid-19 detection capability. The Mammoth Foundation has donated BGI-produced testing equipment along with installation, training and logistics support. One of the major pieces of equipment that has been donated is the MGISP-960 automated viral RNA extraction and sample preparation robot. This equipment will decrease manual processing time, increase testing efficiency and safety.

MedC2 has received approval from the European Commission for a subsidy worth €860,000 as part of international project DRAGON launch, spearheaded by OncoRadiomics. MedC2 mainly focusses on oncology and is now aiming to develop three applications to empower people who may or may not exhibit Covid-19 symptoms, support doctors who carry out the patient triage and facilitate efficient participants inclusion for clinical trials related to the coronavirus.